Luciole is a start-up biotechnology company discovering and developing small molecule activators of OGG1, to accelerate the repair of oxidative damage to mitochondrial DNA. Parkinson's disease (PD), a leading cause of death throughout the world, is a very common and serious incurable disease of the brain. By targeting a novel therapeutic target, Luciole Pharmaceuticals is developing first-in-class agents as disease-modifying therapeutics for PD. Our efforts have the potential to lead to the discovery of a novel, safe, and very effective oral medicine for PD, which will improve patients' quality-of-life and increase their life expectancy.